Related Experiment Videos

[Impact of RelA antisense oligonucleotides on laryngeal carcinoma Hep-2 cell proliferation]

Song Pan1, Jingzhi Wan, Lilian Wu

  • 1Department of Otolaryngology-Head and Neck Surgery, the Affiliated Hospital of Xianning University, Xianning, 437100, China.

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal of Clinical Otorhinolaryngology Head and Neck Surgery
|March 15, 2011
PubMed
Abstract

Insights

RelA antisense oligonucleotides effectively inhibit laryngeal carcinoma Hep-2 cell proliferation by reducing RelA gene and protein expression. This targeted approach suppressed cell growth and colony formation in vitro.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Context:

  • Laryngeal carcinoma is a significant global health concern.
  • RelA is a key component of the NF-κB signaling pathway, often implicated in cancer progression.
  • Targeting specific molecular pathways offers a promising strategy for cancer treatment.

Purpose:

  • To investigate the efficacy of RelA antisense oligonucleotides in inhibiting laryngeal carcinoma Hep-2 cell proliferation.
  • To assess the impact of RelA inhibition on cell growth, colony formation, and gene/protein expression.

Summary:

  • RelA antisense oligonucleotides were designed and introduced into laryngeal carcinoma Hep-2 cells.
  • MTT assays demonstrated a time-dependent inhibition of Hep-2 cell proliferation.
  • Colony formation assays and molecular analyses (RT-PCR, Western blot) confirmed significant suppression of RelA mRNA and protein expression.

Impact:

  • RelA antisense oligonucleotides significantly suppress laryngeal carcinoma cell proliferation.
  • This inhibition is associated with reduced RelA gene and protein expression.
  • The findings suggest potential therapeutic applications of RelA-targeted antisense oligonucleotides in laryngeal cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...